Background {#Sec1}
==========

About 85 % of cases of adult acute lymphoblastic leukemia (ALL) develop from B-cells. Identification of biological determinants of treatment-outcomes is incomplete. Consensus prognostic variables include age, gender, WBC level at diagnosis, cytogenetic abnormalities, *BCR-ABL1*, central nervous system (CNS) leukemia, time to initial response and detection of measureable residual disease (MRD) after induction and consolidation therapies \[[@CR1]--[@CR5]\]. However, analyses of receiver-operator characteristic (ROC) curves indicate only about one-half of the variability in subject-level outcomes is explained by known prognostic variables \[[@CR6]\].

Genome-wide analyses indicate *IKZF1* mutations are common in ALL and are associated with *BCR-ABL1* \[[@CR7], [@CR8]\]. *IKZF1* encodes the Ikaros transcription factor, a member of a family of zinc-finger nuclear proteins required for normal lymphoid development \[[@CR9]\]. Intra-genic deletions in *IKZF1* generate aberrant isoforms \[[@CR8], [@CR10]\]. The role of *IKZF1* deletions is extensively-evaluated in children with ALL and is the most common genetic marker associated with a poor prognosis \[[@CR11]--[@CR15]\]. *IKZF1* mutations are also common in adults with B-cell ALL and are also associated with poor prognosis in persons with concurrent *BCR-ABL1* \[[@CR16]--[@CR18]\]. Few data are available on the role of *IKZF1* deletions in adults with common B-cell ALL. In preliminary analyses we found frequent *IKZF1* deletions in this population. Based on these data we interrogated associations between *IKZF1* deletion and prognosis in a series of adults with common B-cell ALL.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

Between April, 2007 and December, 2012 165 newly-diagnosed subjects ≥14 years old with common B-cell ALL were seen at Peking University People's Hospital, Peking University Institute of Hematology (Beijing, China). 3 subjects with severe co-morbidities were ineligible for induction chemotherapy (2 had an *IKZK1* deletion) and excluded from further analyses. The 162 eligible subjects received remission-induction chemotherapy. Those achieving complete remission received 2 cycles of consolidation chemotherapy after which they could continue receiving chemotherapy or receive an allotransplant based on donor availability, finances and physician and subject choice. Physicians and subjects were blinded to results of *IKZF1*-testing. Subjects were followed until death, loss to follow-up or December, 2014. Written informed consent was obtained from adult subjects and from parents of minors in accordance with the Declaration of Helsinki. The study was approved by the Ethics Committee of Peking University People's Hospital. Subjects receiving post-remission chemotherapy were included in a Chinese Clinical Trial registered in 2007 with the Beijing Municipal Government (Beijing Municipal Health Bureau Registration N: 2007--1007).

Diagnosis and response criteria {#Sec4}
-------------------------------

Diagnosis of ALL was based on ≥20 % bone marrow lymphoblasts. Common-B-cell type was defined as cases with CD10, CD19, CD22 and CD79a expression and no surface immunoglobulin by flow cytometry \[[@CR19]\]. Complete remission was defined bone marrow lymphoblasts \< 5 %, neutrophils \>1.0 × 10E + 9/L, platelets \>100 × 10E + 9/L, no extra-medullary disease and no loss of these features for \>4 weeks. Relapse was defined as leukemia recurrence at any site in persons in complete remission.

Cytogenetic and molecular analyses {#Sec5}
----------------------------------

Cytogenetic analyses were performed by using standard G-banding \[[@CR20]\]. *BCR-ABL1* transcripts, *MLL* rearrangement and *E2A/PBX1* transcripts were detected with quantitative real-time polymerase chain reaction (RQ-PCR) \[[@CR21], [@CR22]\]. *IKZF1* deletions were detected using multiplex RQ-PCR, multiplex fluorescent PCR, sequence analysis \[[@CR23]\] and multiplex ligation-dependent probe amplification (MLPA) (MRC-Holland, Amsterdam, Netherlands) performed using SALSA MLPA kit P202-B1 *IKZF1*. Focal *IKZF1* gene deletions (deletions of exons 4--7, 4--8, 2--7, 2--8 and other focal deletions identified by MLPA analysis) were defined as *IKZF1* deletion in the present study.

Chemotherapy {#Sec6}
------------

One hundred six subjects without BCR/ABL received induction chemotherapy with 1--2 cycles of CODPL (cyclophosphamide, vincristine, daunorubicin, prednisone and L-asparaginase). 56 subjects with *BCR-ABL1* received induction chemotherapy with the same regimen without L-asparaginase and 48 also received imatinib, 400 mg/d, beginning at diagnosis. 5 were later switched to dasatinib, 1 to nilotinib and 1 to ponatinib because of resistant mutations. Data regarding *IKZF1* deletion were not used to determine induction chemotherapy. Subjects achieving complete remission (CR) received 2 cycles consolidation chemotherapy with hyper-CVAD (cyclophosphamide, vincristine, doxorubincin, dexamethasone, cytarabine and methotrexate). All subjects received CNS prophylaxis with intrathecal methotrexate, cytarabine and dexamethasone for ≥8 doses during induction and consolidation therapy. Details of these regimens are reported \[[@CR24]\]. Subjects remaining in CR continued receiving chemotherapy until the completed 6 more cycles, received an allotransplant or relapsed. Post-consolidation therapy was with 6-mercaptopurine, 50 mg/mE2/d PO and methotrexate, 20 mg/mE2/d PO, each once weekly. 28 subjects with *BCR-ABL1* receiving an allotransplant also received posttransplant tyrosine kinase-inhibitor (TKI) therapy. 17 subjects with *BCR-ABL1* receiving post-consolidation chemotherapy but no allotransplant also received post-consolidation TKI therapy. Decisions to give or not to give TKI therapy post-consolidation or posttransplant were based on finances and subject and/or physician preference and without knowing results of *IKZF1* deletion-testing.

Allotransplants {#Sec7}
---------------

Ninety-two subjects (64 %) received an allotransplant, 24 (26 %) from an HLA-identical sibling and 68 (74 %) from a HLA-haplotype-mismatched related donor (1 HLA-antigen mismatch \[*N* = 4\], 2 HLA-antigen mismatches \[*N* = 20\] and 3 HLA-antigen mismatches \[*N* = 44\]). Conditioning was with busulfan and cyclophosphamide. Anti-thymocyte globulin was given pretransplant when the donor was a HLA-haplotype-mismatched relative. Donors received recombinant human G-CSF after which bone marrow and blood cells were collected and infused into the recipient. Graft-vs.-host disease prophylaxis was with cyclosporine, mycophenolatemofetil and short-term methotrexate. Haematological relapses were treated with donor mononuclear cells infusions. Some subjects received a 2^nd^ transplant from the same or a different donor. Details are reported \[[@CR25], [@CR26]\].

Endpoints and statistical analyses {#Sec8}
----------------------------------

Haematologic response was analyzed weekly for the first 3 months and monthly thereafter. Cytogenetic and molecular responses were analyzed every 3 months for the first 6 months and every 6--12 months thereafter. Leukemia-free survival (LFS) was calculated from the date of 1^st^ complete remission to the date of first relapse or death in complete remission. Survival was calculated from 1^st^ complete remission to the date of death from any cause. Observations were censored at the date of last contact or December, 2014 when no events were observed. In survival analyses subjects receiving an allotransplant who relapsed were censored at the time they received a donor blood cell infusion or a second allotransplant. Last follow-up was December, 2014. Relapse was defined as 1^st^ hematologic relapse regardless of site. Independence of categorized parameters was calculated using Chi-square test (or Fisher Exact test). Distribution of continuous variables was calculated using Wilcoxon two sample tests. Survival functions were estimated by the Kaplan-Meier method and compared by the log-rank test. Cumulative incidences were estimated for NRM and relapse to accommodate competing risks. NRM was a competing risk for relapse and death from any cause was a competing risk for relapse. A Cox proportional hazard regression model was used to determine associations between *IKZF1* deletion and other variables with relapse, NRM, treatment-failure and death. The variables to be considered in the multivariate models were: *IKZF1* deletion (Y/N), *BCR-ABL1* (Y/N), gender, age (≥ vs. \< 35 years), WBC (≥ vs. \< 30 × 10E + 9/L), hypo-diploid karyotype (Y/N), complex karyotype and treatment (chemotherapy vs. allotransplant). CNS, *MLL* rearrangement or *E2A-PBX1* transcripts and TKI were not considered in the multivariate analysis because of either too few subjects in a category or missing data. Assumption of proportional hazards for each factor in the Cox model was tested using time-dependent covariates. A stepwise model selection approach was used to identify all significant risk factors. Each step of model building contained the main effect for *IKZF1* deletion. Factors which are significant at a *P* = 0.05 level were kept in the final model. Potential interactions between main effect and all significant risk factors were tested. Analyses were performed by SPSS software version 19.0 (Chicago, IL, USA), Graphpad Prism 5.01 (San Diego, California, USA) and R version 3.1.2. Difference with *P* \< 0.05 was considered significant.

Results {#Sec9}
=======

Subjects {#Sec10}
--------

Sixty-eight *IKZF1* local deletions were detected of subjects achieving complete remission including 32 (47 %) subjects with type Δ4--7, 17 (25 %) with type Δ2--7, 3 with type Δ4--8, 10 (15 %) with type Δ2-8 and 6 with other deletions. 6 other deletions identified by MLPA analysis were undetectable by multiplex PCR. Proportions of dominant negative isoforms (Δ4--7 deletion) and haplotype-insufficiency (other local deletion types) were comparable. The proportion of Δ4--7 deletion in subjects with *BCR-ABL1* was higher than in subjects without *BCR-ABL1* (20/31 vs. 12/37; *P* = 0.008). Baseline subject- and disease-related variables of subjects achieving CR are shown in Table [1](#Tab1){ref-type="table"}. Subjects with *IKZF1* deletion were older (34 years \[15--70\] vs. 22 \[14--59\]; *P* = 0.045), had a significantly higher WBC (14 \[2--435\] vs. 9 \[0.5--168\]; *P* = 0.008) and were more likely to have *BCR-ABL1* (75 % vs. 25 %; *P* \< 0.01) and t (9; 22) (72 % vs. 28 %; *P* \< 0.05) than subjects without *IKZF1* deletion.Table 1Subject- and disease-related variablesVariableAll subjects*IKZF1*-deleted*IKZF1* wild type*P-*value*N*14668 (47 %)78 (53 %)Age, y Median (range)27 (14--70)34 (15--70)22 (14--59)0.045Gender Male7233 (46 %)39 (54 %)0.859WBC (×10E + 9/L) Median (range)10 (0.5-435)14 (2--435)9 (0.5-168)0.008Hemoglobin (g/L) Median (range)90 (23--157)92 (35--148)89 (23--157)0.300Platelets (×10E + 9/L) Median (range)57 (0.2--313)58 (0.2--311)52 (2--313)0.600Bone marrow blasts, % Median (range)87 (28--99)86 (28--98)88 (28--99)0.300  *BCR-ABL1*5239 (75 %)^a^13 (25 %)^b^0.000Cytogenetics Normal4719 (40 %)28 (60 %)0.305 Abnormal8138 (47 %)43 (53 %)  t(9;22)4331 (72 %)12 (28 %)0.000  t(X;2)(p22;p21)110  del(9)(p13)110  inv(9)211  47,+X110  Complex33330 Unknown1811 (61 %)7 (39 %)^a^8 subjects with *BCR-ABL1* had no t(9;22) including 5 with insufficient metaphases, 2 with an abnormal karyotype but not t(9;22) and 1 with a normal karyotype^b^1 subject with *BCR-ABL1* had a normal karyotype

Outcomes and *IKZF1* deletion {#Sec11}
-----------------------------

Median follow-up was 22 months (range, 2--91 months). 146 (90 %) subjects achieved complete remission. 2 subjects in the *IKZF1* cohort relapsing during consolidation chemotherapy and before they could be assigned to further chemotherapy-only or an allotransplant were excluded from further analyses. 5-year NRM in the 144 subjects was 14 % (95 % confidence interval \[CI\], 6--22 %), 5-year CIR was 38 % (27--49 %), 5-year LFS, 48 % (36--59 %) and 5-year survival, 63 % (51--72 %). In subjects with *IKZF1* deletion 5-year NRM was 11 % (2--20 %) vs. 16 % (4--28 %; *P* = 0.736, Fig. [1a](#Fig1){ref-type="fig"}) for subjects without *IKZF1* deletion. In subjects with *IKZF1* deletion 5-year CIR was 55 % (35--76 %) vs. 25 % (12--38 %; *P* = 0.004; Fig. [1b](#Fig1){ref-type="fig"}) for subjects without *IKZF1* deletion. In subjects with *IKZF1* deletion 5-year LFS was 33 % (16--52 %) vs. 59 % (42--73 %; *P* = 0.012; Fig. [1c](#Fig1){ref-type="fig"}) in subjects without *IKZF1* deletion. In subjects with *IKZF1* deletion 5-year survival was 48 % (33--62 %) vs. 75 % (57--86 %; *P* = 0.002; Fig. [1d](#Fig1){ref-type="fig"}) in subjects without *IKZF1* deletion. There were 26 deaths in *IKZF1* deletion cohort, 20 from leukemia and 6 from other causes. There were 15 deaths in the no *IKZF1* deletion cohort, 5 from leukemia and 10 from other causes. Prognoses were similar in subjects with a dominant negative *IKZF1* isoform compared to haplotype-insufficient subjects: 4-year NRM 14 % (1--27 %) vs. 8 % (0--19 %; *P* = 0.32); 4-year CIR 50 % (29--70 %) vs. 44 % (23--64 %; *P* = 0.54); 4-year LFS 36 % (18--55 %) vs. 49 % (28--67 %; *P* = 0.20) and 4-year survival 45 % (23--65 %) vs. 51 % (30--69 %; *P* = 0.53).Fig. 1**a** Cumulative incidence of non-relapse mortality (NRM); **b** cumulative incidence of relapse (CIR); **c** leukemia-free survival (LFS); and **d** survival of subjects with and without *IKZF1* deletion since first complete remission

Because *IKZF1* deletion and *BCR-ABL1* were confounded (*r* = 0.407; *P* \< 0.001), we analyzed the impact of *IKZF1* deletion in subjects with and without *BCR-ABL1*. Amongst the 94 subjects without *BCR-ABL1* the 65 subjects with *IKZF1* deletion had a significantly higher 4-year CIR than the 29 subjects without *IKZF1* deletion (51 % \[30--72 %\] vs. 17 % \[7--28 %\]; *P* = 0.002). These subjects also had worse LFS (33 % \[15--52 %\] vs. 72 % \[58--82 %\]; *P* = 0.001) and worse survival (46 % \[24--66 %\] vs.84 % \[71--91 %\]; *P* = 0.000). There was no significant difference in their NRM (17 % \[1--32 %\] vs. 11 % \[2--19 %\]; *P* = 0.525). In contrast, there were no significant differences in NRM, CIR, LFS or survival in subjects with *BCR-ABL1* with and without *IKZF1* deletion.

Interaction between *IKZF1* deletion and post-remission therapy {#Sec12}
---------------------------------------------------------------

Fifty-two subjects achieving remission received chemotherapy-only. 3-year NRM was 15 % (3--26 %), 3-year CIR, 53 % (36--70 %), 3-year LFS, 32 % (17--49 %) and 3-year survival, 44 % (23--64 %). Subjects with *IKZF1* deletion (*N* = 28) had similar 3-year NRM (14 % \[0--29 %\] vs. 15 % \[0--33 %\]; *P* = 0.958), 3-year CIR (73 % \[41--100 %\] vs. 39 % \[16--61 %\]; *P* = 0.099), worse 3-year LFS (14 % \[1--41 %\] vs. 46 % \[23--66 %\]; *P* = 0.084) and worse 3-year survival (15 % \[1--44 %\] vs.78 % \[48--92 %\]; *P* = 0.001; Fig. [2a-d](#Fig2){ref-type="fig"}) compared with subjects without *IKZF1* deletion.Fig. 2NRM, CIR, LFS and survival of subjects with and without *IKZF1* deletion receiving chemotherapy-only (**a**-**d**) or an allotransplant (**e**-**h**) since 1^st^ complete remission. Abbreviations: NRM, non-relapse mortality; CIR, cumulative incidence of relapse; LFS, leukemia-free survival; CR1, 1^st^ complete remission

Ninety-two (64 %) subjects achieving remission received an allotransplant. 5-year NRM was 14 % (4--24 %), 5-year CIR, 31 % (17--45 %), 5-year LFS, 56 % (40--70 %) and 5-year survival, 71 % (56--81 %). Subjects with *IKZF1* deletion (*N* = 38) had a significantly higher 5 year CIR (47 % \[21--73 %\] vs. 20 % \[3--36 %\]; *P* = 0.024) but similar 5 years NRM (9 % \[0--19 %\] vs. 17 % \[1--33 %\]; *P* = 0.567), 5-year LFS (44 % \[21--66 %\] vs. 64 % \[40--80 %\]; *P* = 0.119) and 5-year survival (64 % \[44--79 %\] vs.75 % \[53--88 %\]; *P* = 0.332; Fig. [2e](#Fig2){ref-type="fig"}-[h](#Fig2){ref-type="fig"}).

Multivariate analyses {#Sec13}
---------------------

*IKZF1* deletion was independently associated with an increased relapse risk (*RR* = 2.7 \[1.4--5.2\]; *P* = 0.002), a greater risk of treatment-failure (*RR* = 2.1 \[1.2--3.6\]; *P* = 0.007) and a greater risk of death (*RR* = 2.8 \[1.5--5.5\]; *P* = 0.002). An adverse impact of *IKZF1* on survival was observed in subjects receiving chemotherapy-only (*RR* = 6.5 \[2.1--19.7\]; *P* = 0.001) but not those receiving an allotransplant (*RR* = 1.5 \[0.7--3.6\]; *P* = 0.336). Other variables associated with relapse were chemotherapy-only (*RR* = 6.0 \[3.1--11.6\]; *P* \< 0.0001) and male gender (*RR* = 2.0 \[1.1--3.9\]; *P* = 0.030). Chemotherapy-only was also associated with greater risk of treatment-failure (*RR* = 4.4 \[2.6--7.6\]; *P* \< 0.0001) and death (*RR* = 4.1 \[2.1--7.8\]; *P* \< 0.0001). Age ≥35 years was the only variable associated with NRM (*RR* = 3.0 \[1.1--8.7\]; *P* = 0.039). Results of multivariate analyses are shown in Table [2](#Tab2){ref-type="table"}.Table 2Multivariate analyses of NRM, relapse, treatment-failure and deathOutcome*N*RR (95 % CI)*P*NRM  *IKZF1* deleted vs. not deleted66/780.8 (0.3--2.2)0.630 Age: ≥ vs. \< 35 y55/893.0 (1.1--8.7)0.040Relapse  *IKZF1* deleted vs. not deleted66/782.7 (1.4--5.2)0.002 Chemotherapy vs. transplant52/926.0 (3.1--11.6)0.000 Male vs. female73/712.0 (1.1--3.9)0.030Treatment-failure  *IKZF1* deleted vs. not deleted66/782.1 (1.2--3.6)0.007 Chemotherapy vs. transplant52/924.4 (2.6--7.6)0.000Death  *IKZF1* deleted vs. not deleted66/782.8 (1.5--5.6)0.002 Chemotherapy vs. transplant52/924.1 (2.1--7.8)0.000Chemotherapy  *IKZF1* deleted vs. not deleted28/246.5 (2.1--19.7)0.001Transplant  *IKZF1* deleted vs. not deleted38/541.5 (0.7--3.6)0.336*Abbreviation*: *NRM* non-relapse mortality, *RR* relative risk, *CI* confidence interval

Discussion {#Sec14}
==========

*IKZF1* deletion was independently-associated with higher risks of relapse, treatment-failure and death in adults with common B-cell ALL compared with similar subjects without *IKZF1* deletion. Although *IKZF1* deletion was confounded with *BCR-ABL1*, the adverse impact persisted after adjusting for *BCR-ABL1* and parallels similar findings in children with B-cell ALL \[[@CR12], [@CR15]\]. The adverse impact of *IKZF1* deletion operated mainly in subjects without *BCR-ABL1*. In subjects receiving an allotransplant the adverse impact of *IKZF1* deletion was less than in those receiving chemotherapy-only suggesting a benefit for using transplants in subjects with *IKZF1* deletion.

Our analysis was complex because of confounding between *IKZF1* deletion, *BCR-ABL1* and post-remission therapy (chemotherapy-only vs. an allotransplant). We used multivariate analyses to resolve this confounding. We found *IKZF1*deletion, chemotherapy-only, gender and age were significantly associated with outcomes whereas other variables including WBC, cytogenetics and *BCR-ABL1* were not. This is surprising, especially the lack of a significant association between *BCR-ABL1* with outcomes. There are several possible explanations. One is insufficient statistical power; there were relatively few subjects with adverse cytogenetics, hypo-diploidly or a complex karyotype. However, low power cannot explain the lack of a significant association between *BCR-ABL1* and outcomes. As indicated, *IKZF1* deletion and *BCR-ABL1* were confounded. Subjects with *BCR-ABL1* received different initial therapy than subjects without *BCR-ABL1* including TKIs in 90 % and an allotransplant in 58 %. If these interventions were highly-effective they could mitigate the adverse impact of *BCR-ABL1*. This notion is supported by the observation the adverse predictive impact of *IKZF1* deletion was detected in subjects without but not in those with *BCR-ABL1* and in subjects receiving chemotherapy-only but not in those receiving an allotransplant.

Our conclusions contrast with data from a study of 83 subjects with *BCR-ABL1* which reported *IKZF1* deletions were associated with more relapses and worse LFS \[[@CR16]\]. However, there are several important differences in subjects (we studied only subjects with common B-cell ALL) and post-remission therapy (few of their subjects received an allotransplant). Our conclusion is similar to reports in children with *BCR-ABL1* in whom *IKZF1* deletion is associated with worse outcomes and with results of a recent meta-analysis indicating *IKZF1* deletion is independently-associated with worse outcomes in children and adults with ALL \[[@CR27], [@CR28]\].

There are several limitations to our study. One, as discussed, is confounding between *IKZF1* deletion, *BCR-ABL1* and post-remission therapy. Confounding is difficult to satisfactorily sort out in multivariate analyses but our data suggest that *IKZF1* deletion was independently-associated with higher risks of relapse, treatment-failure and death in subjects without *BCR-ABL1*. Second, subjects with *BCR-ABL1* received different induction, consolidation and post-remission therapies than those without *BCR-ABL1*. However, therapy-assignment was made without knowing *IKZF1* deletion data and we tried to account for this complexity in multivariate analyses. Another limitation is we did not include several potentially important variables (CNS leukemia, *MLL* rearrangement, *E2A-PBX1* transcripts and TKI therapy) in the multivariate analyses because of too few subjects or missing data. The sum of these potential limitations means our conclusions require confirmation in prospective, randomized studies.

Conclusion {#Sec15}
==========

In adults with common B-cell ALL achieving complete remission *IKZF1* mutation was independently-associated with a higher CIR and worse survival than subjects without *IKZF1* mutation. These differences were greater in subjects receiving post-remission chemotherapy than in subjects receiving an allotransplant. We suggest a randomized trial to confirm our observation.
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